News

Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?
We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...
Medical Dialogues17h
Bristol Myers Squibb, BioNTech ink pact to co-develop, co-commercialize investigational bispecific antibody for multiple solid tumor types
Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...
Bristol-Myers Squibb Company: Markey Researchers Awarded $6.8 Million To Help Others Replicate Kentucky's Lung Cancer Screening Success
PRINCETON, NJ / ACCESS Newswire / June 6, 2025 / Originally published on University of Kentucky Research NewsA groundbreaking lung cancer screening project co-led by the University of Kentucky Markey ...
Bristol Myers Collaborates With BNTX for Oncology Candidate
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid ...
Fierce Pharma3d
ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flop
Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...
Why BioNTech Stock Soared Today
Bristol Myers Squibb just agreed to shower BioNTech with cash. BioNTech ( BNTX 20.01%), one of the companies made famous for ...
BioWorld4d
Biontech trades half of bispecific BNT-327 to BMS for potential $11B+
Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 ...
BioNTech-Aktie steigt - Bristol zahlt bis zu $11,1 Mrd. in Krebsmedikament-Deal
Bristol-Myers Squibb wird BioNTech bis zu 11,1 Milliarden Dollar (9,7 Milliarden Euro) für die Lizenzierung eines ...